var data={"title":"Fenofibrate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fenofibrate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/698810?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fenofibrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fenofibrate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49638570\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Antara;</li>\n      <li>Fenoglide;</li>\n      <li>Fibricor;</li>\n      <li>Lipofen;</li>\n      <li>Lofibra;</li>\n      <li>Tricor;</li>\n      <li>Triglide;</li>\n      <li>Trilipix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370290\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lipidil EZ;</li>\n      <li>Lipidil Supra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370293\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, Fibric Acid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370331\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> At least 2 to 3 months of therapy is required to determine efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertriglyceridemia:</b> Oral: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antara (micronized): 30 to 90 mg once daily; maximum dose: 90 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fenofibrate (micronized): 43 to 130 mg once daily; maximum dose: 130 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fenoglide: 40 to 120 mg once daily; maximum dose: 120 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fibricor: 35 to 105 mg once daily; maximum dose: 105 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil EZ [Canadian product]: 145 mg once daily; maximum dose: 145 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil Supra [Canadian product]: 160 mg once daily; maximum dose: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipofen: 50 to 150 mg once daily; maximum dose: 150 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lofibra (micronized): 67 to 200 mg once daily; maximum dose: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lofibra (tablets): 54 to 160 mg once daily; maximum dose: 160 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TriCor: 48 to 145 mg once daily; maximum dose: 145 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Triglide: 160 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trilipix: 45 to 135 mg once daily; maximum dose: 135 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercholesterolemia or mixed hyperlipidemia:</b> Oral: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antara (micronized): 90 mg once daily; maximum dose: 90 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fenofibrate (micronized): 130 mg once daily; maximum dose: 130 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fenoglide: 120 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fibricor: 105 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil EZ [Canadian product]: 145 mg once daily; maximum dose: 145 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil Supra [Canadian product]: 160 mg once daily; maximum dose: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipofen: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lofibra (micronized): 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lofibra (tablets): 160 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TriCor: 145 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Triglide: 160 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trilipix: 135 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370332\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Initial: Adjust dosage based on renal function; additional product-specific recommendations for initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipidil EZ [Canadian product]: 48 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofibra (micronized): 67 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofibra (tablets): 54 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370333\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function and lipid panel before adjusting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antara (micronized):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute or eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute or eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute or eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate (micronized):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute or eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute or eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 43 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute or eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenoglide:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute or eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute or eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute or eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibricor:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute: Initiate at 35 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipidil EZ [Canadian product]: <b>Note:</b> Interrupt treatment in patients with an increase in CrCl &gt;50% the upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 60 mL/minute: 48 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipidil Supra [Canadian product]: <b>Note:</b> Interrupt treatment in patients with an increase in CrCl &gt;50% the upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 60 mL/minute: Initial: 100 mg once daily; titrate cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipofen:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &ge;90 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>: Initiate at 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofibra (micronized):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute: Initiate at 67 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofibra (tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 54 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TriCor:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 48 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triglide:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute or eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 80 mL/minute or eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute or eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trilipix:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initiate at 45 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370334\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated. Regular monitoring of liver function tests is required; discontinue therapy in patients whose enzyme levels persist above 3 times the upper limit of normal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22549100\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cholelithiasis:</i> Discontinue if gallstones are found upon gallbladder studies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>CPK elevation, myopathy, and/or myositis:</i> Discontinue therapy if the patient develops markedly elevated CPK concentrations or if myopathy/myositis is suspected or diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>HDL-C reductions:</i> Permanently discontinue therapy if HDL-C becomes severely depressed; monitor HDL-C concentrations until returned to baseline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49638571\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as fenofibrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antara: 30 mg, 43 mg [DSC] [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antara: 90 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antara: 130 mg [DSC] [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipofen: 50 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipofen: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lofibra: 67 mg, 134 mg, 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 43 mg, 50 mg, 67 mg, 130 mg, 134 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as choline fenofibrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trilipix: 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trilipix: 135 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 45 mg, 135 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as fenofibrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fenoglide: 40 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lofibra: 54 mg [contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lofibra: 160 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tricor: 48 mg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tricor: 145 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triglide: 160 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triglide: 160 mg [contains egg phospholipids (egg lecithin)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg, 48 mg, 54 mg, 120 mg, 145 mg, 160 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as fenofibric acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fibricor: 35 mg, 105 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 35 mg, 105 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49638569\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370348\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Micronized formulations: Antara, Lofibra capsules</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strength of choline fenofibrate products are expressed in terms of fenofibric acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50134064\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the United States. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as fenofibrate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil EZ: 48 mg, 145 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil Supra: 160 mg [contains soybean lecithin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22625620\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">TriLipix: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089806.pdf%20&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlrMbRDcT8kxUd9MPMsdj1rKrQqOdo+LC9sZESPPydEAM=&amp;TOPIC_ID=91482\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089806.pdf </a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370337\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antara, fenofibrate (micronized), Fibricor, Lipidil EZ [Canadian product], Lofibra tablets, TriCor, Triglide, Trilipix: Administer with or without food. Swallow whole; do not open (capsules), crush, dissolve, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lofibra (micronized) capsules: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fenoglide, Lipofen, Lipidil Supra [Canadian product], Lipidil Supra [Canadian product]: Administer with meals. Swallow whole; do not open (capsules), crush, dissolve, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370297\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercholesterolemia or mixed dyslipidemia:</b> Adjunctive therapy to diet for the reduction of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb). Use lipid-altering agents in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>While FDA-approved for hypercholesterolemia, fenofibrate is not a first- or second-line choice; other agents may be more suitable (ACC/AHA [Stone 2013]). In addition, use is not recommended to lower LDL-C or raise HDL-C in the absence of hypertriglyceridemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertriglyceridemia:</b> Adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370285\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fibricor may be confused with Tricor</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">TriCor may be confused with Fibricor, Tracleer</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">TriLipix may be confused with Trileptal, TriLyte</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370307\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Pulmonary embolism (&le;5%), thrombophlebitis (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Pain (1% to 4%), dizziness (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (1%), urticaria (1%), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (5%), diarrhea (&ge;3%), dyspepsia (&ge;3%), cholecystitis (requiring surgery: 2%), constipation (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, decreased hematocrit (acute; levels stabilize with chronic therapy), decreased hemoglobin (acute; levels stabilize with chronic therapy), decreased white blood cell count (acute; levels stabilize with chronic therapy), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (&le;13%; &gt;3 x ULN; dose dependent), increased serum AST (&le;13%; &gt;3 x ULN; dose dependent), abnormal hepatic function tests (8%), cholestatic hepatitis, chronic active hepatitis, hepatocellular hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (&ge;3%), limb pain (&ge;3%), myalgia (&ge;3%), increased creatine phosphokinase (3%), myopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis (&ge;3%), sinusitis (&ge;3%), upper respiratory tract infection (&ge;3%), rhinitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anemia, arthralgia, decreased HDL cholesterol, hepatic cirrhosis, hepatitis, increased serum creatinine, muscle spasm, myalgia, pancreatitis, renal failure, rhabdomyolysis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370304\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fenofibrate or fenofibric acid or any component of the formulation; active liver disease, including primary biliary cirrhosis and unexplained, persistent liver function abnormality; severe renal impairment or end-stage renal disease (ESRD), including those receiving dialysis; preexisting gallbladder disease; breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for fibrates is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lipidil EZ, Lipidil Supra: Additional contraindications: Allergy to soya lecithin, peanut or arachis oil, or related products; chronic or acute pancreatitis; patients &lt;18 years of age; coadministration with HMG-CoA reductase inhibitors in patients with a predisposition for myopathy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370305\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholelithiasis: May cause cholelithiasis; discontinue if gallstones are found upon gallbladder studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HDL cholesterol (HDL-C): A paradoxical, severe, and reversible decrease in HDL-C (as low as 2 mg/dL) with a simultaneous decrease in apolipoprotein A1 has been reported within 2 weeks to years after initiation of fibrate therapy; clinical significance unknown. Monitor HDL-C within a few months of initiation of therapy and discontinue if HDL-C becomes severely depressed; do not restart therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: May cause mild-to-moderate decreases in hemoglobin, hematocrit and WBC upon initiation of therapy which usually stabilizes with long-term therapy. Agranulocytosis and thrombocytopenia have been reported. Periodic monitoring of blood counts is recommended during the first year of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic transaminases can become significantly elevated (dose-related); hepatocellular, chronic active, and cholestatic hepatitis have been reported after weeks to several years of therapy. Baseline and regular monitoring of liver function tests is required; discontinue therapy in patients whose enzyme levels persist above 3 times the upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Acute hypersensitivity reactions (eg, severe skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Has been associated with rare myositis, myopathy, or rhabdomyolysis; monitor patients closely. Risk increased in the elderly, those receiving concomitant HMG-CoA reductase inhibitors or colchicine, and patients with diabetes mellitus, renal insufficiency, or hypothyroidism. Instruct patients to report unexplained muscle pain, tenderness, weakness, especially if accompanied with malaise or fever; or brown urine. Discontinue therapy in patients who develop markedly elevated CPK concentrations or if myopathy/myositis is suspected or diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Pancreatitis has been reported with fenofibrate use; may be secondary to a failure of efficacy in patients with severe hypertriglyceridemia, medication side effect, or due to biliary tract stone or sludge formation from bile duct obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Increases in serum creatinine (&gt;2 mg/dL) have been observed with use; clinical significance unknown. These elevations tend to return to baseline following discontinuation of fenofibrate. Fenofibrate has been shown to increase creatinine production (unknown mechanism) resulting in an equal increase of creatinuria thereby demonstrating that the increase does not reflect a reduction in creatinine clearance (Hottelart 2002). Monitor renal function in patients with renal impairment; consider monitoring renal function in patients with increased risk for developing renal impairment (eg, elderly and patients with diabetes).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Venous thromboembolism (VTE): Use has been associated with pulmonary embolism (PE) and deep vein thrombosis (DVT). Use with caution in patients with risk factors for VTE.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Fibric acid derivatives have not demonstrated significant efficacy in altering cardiovascular disease mortality in major clinical studies. In two large randomized controlled clinical trials, neither fenofibrate monotherapy (Keech 2005) nor the addition of fenofibrate to simvastatin (ACCORD Study Group 2010) compared to placebo were shown to reduce cardiovascular disease morbidity and mortality in patients with type 2 diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Contraindicated in patients with active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild to moderate renal impairment; dosage adjustment required. Contraindicated in patients with severe renal impairment including those receiving dialysis. Avoid use of Triglide in patients with mild or moderate renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HMG-CoA reductase inhibitors: Use caution with HMG-CoA reductase inhibitors; may lead to myopathy, rhabdomyolysis. No incremental benefit of combination therapy on cardiovascular morbidity and mortality over statin monotherapy has been established. In combination with HMG-CoA reductase inhibitors, fenofibrate is generally regarded as safer than gemfibrozil due to limited pharmacokinetic interaction with statins. Fenofibrate may be considered in patients on low- or moderate-intensity statin therapy (ie, statin therapy intended to lower LDL-C by &lt;30% or ~30% to 50%, respectively) only if the benefits from atherosclerotic cardiovascular disease (ASCVD) risk reduction or triglyceride lowering when triglycerides are &gt;500 mg/dL, outweigh the potential risk for adverse effects (ACC/AHA [Stone 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peanut or arachis oil: Some products may contain peanut or arachis oil; use is contraindicated in patients with a peanut or arachis allergy for applicable formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Soya lecithin: Some products may contain soya lecithin; use is contraindicated in patients with a soya lecithin allergy for applicable formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Fenofibrate is not a first- or second-line choice in patients with hypercholesterolemia; other agents may be more suitable (ACC/AHA [Stone 2013]). Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal response: Therapy should be withdrawn if an adequate response is not obtained after 2 to 3 months of therapy at the maximal daily dose. In patients with severe hypertriglyceridemia, the occurrence of pancreatitis may represent a failure of efficacy, a direct effect of the drug, or obstruction of the common bile duct due to biliary tract stone or sludge formation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370312\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak), CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370313\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91482&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<b> Exceptions: </b>Colesevelam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of Fibric Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: Fenofibrate and Derivatives may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Fenofibrate and Derivatives may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): May enhance the nephrotoxic effect of Fenofibrate and Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22549098\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Antara (micronized):</i> When administered under fasted conditions or with a low-fat meal, the extent of absorption and the time to peak did not change; however peak concentrations were increased in the presence of a low-fat meal. When administered with a high fat meal, a 26% increase in the AUC and 108% increase in the peak concentration were seen in comparison to the fasted state. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Fenoglide:</i> When administered with a high-fat meal, the peak concentration was increased by 44% as compared to fasting conditions. Management: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Fibricor:</i> When administered with a high-fat meal, the peak concentration was decreased by ~35% while AUC remained unchanged as compared to fasting conditions. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lipidil EZ [Canadian product]:</i> Bioavailability was not significantly different when administered under fasting and nonfasting conditions. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lipdil Supra [Canadian product]:</i> In general, fenofibrate absorption is low and variable when administered under fasting conditions; absorption is increased when administered with food. Management: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lipofen:</i> When administered with a low-fat and high-fat meal, the extent of absorption is increased by ~25% and ~58%, respectively, as compared to fasting conditions. Management: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lofibra (micronized) capsules:</i> Absorption is increased by ~35% under fed as compared to fasting conditions. Management: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lofibra tablets:</i> Peak concentrations and AUC were not significantly different when a single dose was administered under fasting and nonfasting conditions. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>TriCor:</i> Peak concentrations and AUC were not significantly different when a single dose was administered under fasting and nonfasting conditions. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Triglide:</i> When administered with food, the rate of absorption was increased ~55% as compared to fasting conditions; the AUC remained unchanged. Management: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Trilipix:</i> Peak concentrations and AUC were not significantly different when a single dose was administered under fasting and nonfasting conditions. Management: Administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370300\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370301\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Adverse events were observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Triglyceride and lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. In women who develop very severe hypertriglyceridemia and are at risk for pancreatitis, use of fenofibrate beginning in the second trimester is one intervention that may be considered. Agents other than fenofibrate should be used for hypercholesterolemia (Avis 2009; Berglund 2012; Jacobson 2015; Wong 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370303\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if fenofibrate is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipids are a normal component of breast milk and the fatty acid component is required for normal infant neurologic development. Maternal diet, as well as other factors, may influence the fatty acid composition (Innis 2014). When treatment for very severe hypertriglyceridemia in breastfeeding women at risk for pancreatitis is needed, therapy with fenofibrate may be considered (Jacobson 2015). When treatment is needed for other indications, agents other than fenofibrate are preferred (Jacobson 2015; NICE 2008). The manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370336\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antara, Fibricor, Lipidil EZ [Canadian product], Lofibra tablets, TriCor, Triglide, Trilipix: May be taken with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenoglide, Lipidil Supra [Canadian product], Lipofen, Lofibra (micronized capsules): Take with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370339\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic blood counts during first year of therapy. Monitor lipid profile periodically. Monitor LFTs regularly and discontinue therapy if levels remain &gt;3 times normal limits. Monitor renal function in patients with renal impairment or in those at increased risk for developing renal impairment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Stone 2013]):</i> Evaluate renal status at baseline, within 3 months after initiation, and every 6 months thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370318\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fenofibric acid, an agonist for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha (PPAR-alpha), downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) and upregulates the synthesis of apolipoprotein A-I, fatty acid transport protein, and lipoprotein lipase resulting in an increase in VLDL catabolism, fatty acid oxidation, and elimination of triglyceride-rich particles; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30% to 60%; modest increase in HDL occurs in some hypertriglyceridemic patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370320\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Increased when taken with meals </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to most tissues </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Fenofibrate is metabolized in the tissue and plasma via esterases to the active form, fenofibric acid; fenofibric acid then undergoes inactivation by glucuronidation hepatically or renally </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Fenofibric acid: ~81%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Fenofibric acid: Mean: 20 hours (range: 10 to 35 hours); half-life prolonged in patients with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 2 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~60% as metabolites); feces (25%); hemodialysis has no effect on removal of fenofibric acid from plasma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370351\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Choline Fenofibrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (90): $480.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Trilipix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (90): $324.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (90): $974.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Antara Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $207.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $609.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Fenofibrate Micronized Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">43 mg (30): $70.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">67 mg (100): $105.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">130 mg (30): $207.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">134 mg (100): $195.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $315.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Fenofibrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $293.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (90): $644.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lipofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $366.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (90): $802.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lofibra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">67 mg (100): $185.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">134 mg (100): $357.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fenofibrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $940.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48 mg (90): $171.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (90): $71.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $2,820.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">145 mg (90): $515.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (90): $213.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fenofibric Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (30): $28.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">105 mg (30): $90.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fenoglide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $1,335.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $4,007.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fibricor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (30): $41.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">105 mg (30): $123.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lofibra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (90): $166.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tricor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48 mg (90): $61.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">145 mg (90): $111.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Triglide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (15): $889.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49626998\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apo-Feno (PL);</li>\n      <li>Apo-Feno-Micro (MY);</li>\n      <li>Biofibrat (PL);</li>\n      <li>Catalip (PT);</li>\n      <li>Cholecaps (ID);</li>\n      <li>CIL (FI);</li>\n      <li>Colestrim (TH);</li>\n      <li>Controlip (AR, CR, DO, EC, GT, HN, MX, NI, PA, PE, SV);</li>\n      <li>Cordialibrel (MX);</li>\n      <li>Craveril (AR);</li>\n      <li>Daunlip (AR);</li>\n      <li>Durafenat (DE);</li>\n      <li>Eticer (CN);</li>\n      <li>Evothyl (ID);</li>\n      <li>Exlip (RU);</li>\n      <li>Febira (CZ);</li>\n      <li>Febira 200 (SK);</li>\n      <li>Febrate (TH);</li>\n      <li>Fegenor (FR, LB);</li>\n      <li>Fenacor (IN);</li>\n      <li>Fenardin (PL);</li>\n      <li>Fenatrol (BD);</li>\n      <li>Fenobrat (GR, HU, PE);</li>\n      <li>Fenobrate (AR);</li>\n      <li>Fenobraty (BR);</li>\n      <li>Fenocap (BD);</li>\n      <li>Fenocor (IN);</li>\n      <li>Fenofast (PH);</li>\n      <li>Fenofib (AU);</li>\n      <li>Fenofibraat (BE);</li>\n      <li>Fenofix (CZ, SK);</li>\n      <li>Fenoflex (PH, VN);</li>\n      <li>Fenogal (BE, GB, KW, LB, LU, PH, QA, SA, TR);</li>\n      <li>Fenoget (LK, PK);</li>\n      <li>Fenogetz (VN);</li>\n      <li>Fenolip (AT, CO, HR, IN, RO);</li>\n      <li>Fenopidil (KR);</li>\n      <li>Fenosup (BE, FI, MY, SG);</li>\n      <li>Fenosup Lidose (LB, VN);</li>\n      <li>Fenoswiss (HU);</li>\n      <li>Fiba (LK);</li>\n      <li>Fibra (PK);</li>\n      <li>Fibrafen (PH);</li>\n      <li>Fibral (IN);</li>\n      <li>Fibranor (BG);</li>\n      <li>Fibrate (BD, IN);</li>\n      <li>Fibronil (CL);</li>\n      <li>Fulcro (IT);</li>\n      <li>Fulcrosupra (IT);</li>\n      <li>Grofibrat (PL);</li>\n      <li>Hafenthyl (VN);</li>\n      <li>Hicholfen (ID);</li>\n      <li>Hyperchol (ID);</li>\n      <li>Lenofil (AU);</li>\n      <li>Lexemin (HK, SG, TH);</li>\n      <li>Lifen (ID);</li>\n      <li>Lipanon (BR);</li>\n      <li>Lipanthyl (AE, BE, BG, BH, CH, CN, CZ, DE, EE, EG, FI, FR, HK, ID, JO, KW, LB, LT, LU, LV, MT, MY, PH, PL, QA, RO, RU, SA, SE, SG, SK, TH, TR, VN, ZA);</li>\n      <li>Lipanthyl Supra (MY, SG);</li>\n      <li>Lipantil (GB, IE, RO);</li>\n      <li>Lipantil Supra (MT);</li>\n      <li>Lipcor (AT);</li>\n      <li>Liperial (IT);</li>\n      <li>Lipicard (IN, LK);</li>\n      <li>Lipidil (AU, BR, DE, EC, GR, HR, HU, MX, TR);</li>\n      <li>Lipidil Supra (KR);</li>\n      <li>Lipidof (BD, PK);</li>\n      <li>Lipiduce (PH);</li>\n      <li>Lipifen T.U. (PY);</li>\n      <li>Lipilfen (CN, KR);</li>\n      <li>Lipilo (CN);</li>\n      <li>Lipired (BD);</li>\n      <li>Lipirex (CZ);</li>\n      <li>Lipivim (RO);</li>\n      <li>Lipofen (PT, TR, UA);</li>\n      <li>Lipofib (RO);</li>\n      <li>Lipsin (IT);</li>\n      <li>Lipway (PH);</li>\n      <li>Lofat (BD);</li>\n      <li>Lofibra (PH);</li>\n      <li>Lofibrate (TH);</li>\n      <li>Lolipid (BD);</li>\n      <li>Lowpirol S (KR);</li>\n      <li>Minuslip (AR);</li>\n      <li>Nanofib (LB);</li>\n      <li>Noles (ID);</li>\n      <li>Nopid (KR);</li>\n      <li>Normalip (DE);</li>\n      <li>Normolip (CO, PE);</li>\n      <li>Notricol (CO);</li>\n      <li>Nubrex (PH);</li>\n      <li>Qi Shu (CN);</li>\n      <li>Qualipantyl (HK);</li>\n      <li>Redose (KR);</li>\n      <li>Reducofen (BR);</li>\n      <li>Sclerofin (AR);</li>\n      <li>Sclerofin UD (PY);</li>\n      <li>Secalip (ES, FR, TR);</li>\n      <li>Secalip Retard (ES);</li>\n      <li>Secalip Supra (ES);</li>\n      <li>Stanlip (TH, VN);</li>\n      <li>Sulnit (PY);</li>\n      <li>Sulnit CD (PY);</li>\n      <li>Supralip (GB, PT);</li>\n      <li>Suprelip (CZ, SK);</li>\n      <li>Tilene (IT);</li>\n      <li>Tizabate (BD);</li>\n      <li>Traykor (UA);</li>\n      <li>Trichek (LK, PH);</li>\n      <li>Trichodil (AU);</li>\n      <li>Tricor (HR, JP, RU, UA);</li>\n      <li>Trilipix (CH, CL, RU);</li>\n      <li>Trolip (ID, LK, PH, SG);</li>\n      <li>Ziglip (HR);</li>\n      <li>Zigotrig (HR);</li>\n      <li>Zinof (PH);</li>\n      <li>Zumafib (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACCORD Study Group, Ginsberg HN, Elam MB, et al, &ldquo;Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus,&rdquo; <i>N Engl J Med</i>, 2010, 362(17):1563-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/20228404/pubmed\" target=\"_blank\" id=\"20228404\">20228404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antara (fenofibrate) [prescribing information]. Baltimore, MD: Lupin Pharma; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19741526/pubmed\" target=\"_blank\" id=\"19741526\">19741526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonds DE, Craven TE, Buse J, et al, &quot;Fenofibrate-Associated Changes in Renal Function and Relationship to Clinical Outcomes Among Individuals With Type 2 Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Experience,&quot; <i>Diabetologia</i>, 2012, 55(6):1641-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22450889/pubmed\" target=\"_blank\" id=\"22450889\">22450889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lorgeril M, Salen O, Paillard F, et al, &ldquo;Lipid-Lowering Drugs and Homocyst(e)ine,&rdquo; <i>Lancet</i>, 1999, 353(9148):209-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farnier M, Bonnefous F, Debbas N, et al, &ldquo;Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type IIa or IIb Hyperlipidemia,&rdquo; <i>Arch Intern Med</i>, 1994, 154(4):441-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/8117177/pubmed\" target=\"_blank\" id=\"8117177\">8117177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feher MD, Hepburn AL, Hogarth MB, et al, &ldquo;Fenofibrate Enhances Urate Reduction in Men Treated with Allopurinol for Hyperuricaemia and Gout,&rdquo; <i>Rheumatology (Oxford)</i>, 2003, 42(2):321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/12595630/pubmed\" target=\"_blank\" id=\"12595630\">12595630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenofibrate [prescribing information]. Weston, FL: Apotex Corp; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenofibrate (fenofibric acid) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenoglide (fenofibric acid) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grundy SM, Cleeman JI, Merz CN, et al, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>J Am Coll Cardiol</i>. 2004;44(3):720-732.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/15358046/pubmed\" target=\"_blank\" id=\"15358046\">15358046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hottelart C, El Esper N, Rose F, et al, &quot;Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine,&quot; <i>Nephron</i>, 2002, 92(3):536-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/12372935/pubmed\" target=\"_blank\" id=\"12372935\">12372935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Innis SM. Impact of maternal diet on human milk composition and neurological development of infants. <i>Am J Clin Nutr</i>. 2014;99(3):734S-741S. doi: 10.3945/ajcn.113.072595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/24500153/pubmed\" target=\"_blank\" id=\"24500153\">24500153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 [published correction appears in <i>J Clin Lipidol</i>. 2016;10(1):211]. <i>J Clin Lipidol</i>. 2015;9(6 suppl):S1-S122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26699442/pubmed\" target=\"_blank\" id=\"26699442\">26699442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keech A, Simes RJ, Barter P, et al, &ldquo;Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 People With Type 2 Diabetes Mellitus (The FIELD Study): Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2005, 366(9500):1849-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/16310551/pubmed\" target=\"_blank\" id=\"16310551\">16310551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipidil EZ (fenofibrate) tablets [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipidil Supra (fenofibrate) tablets [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipofen (fenofibrate) capsules [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lofibra (fenofibrate) tablets [prescribing information]. Horsham, PA: Teva Pharmaceuticals; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahley RW and Bersot TP, &ldquo;Drug Therapy for Hypercholesterolemia and Dyslipidemia,&rdquo; <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i>, 10th ed, Hardman JE and Limbird LE, eds, New York, NY: McGraw-Hill, 2001, 993-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. <i>Am Heart J</i>. 2009;157(1):195-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19081418/pubmed\" target=\"_blank\" id=\"19081418\">19081418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mychaleckyj JC, Craven T, Nayak U, et al, &quot;Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants,&quot; <i>Diabetes Care</i>, 2012, 35(5):1008-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22432114/pubmed\" target=\"_blank\" id=\"22432114\">22432114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Care Excellence (2008) Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NICE. (Clinical Guideline 71).Available at http://www.nice.org.uk/CG71.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitori CR, Montanari G, Gianfranceschi G, et al, &ldquo;Correlation Between Plasma Levels of Fenofibrate and Lipoprotein Changes in Hyperlipidaemic Patients,&rdquo; <i>Eur J Clin Pharmacol</i>, 1985, 28(6):619-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/3840743/pubmed\" target=\"_blank\" id=\"3840743\">3840743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taskinen M, Sullivan DR, Ehnholm, et al, &ldquo;Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate,&rdquo; <i>Arterioscler Thromb Vasc Biol</i>, 2009, 29(6):950-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19325138/pubmed\" target=\"_blank\" id=\"19325138\">19325138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tricor (fenofibrate) tablets [prescribing information]. North Chicago, IL: Abbott Laboratories; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triglide (fenofibric acid) [prescribing information]. Flowood MS: SkyePharma Production SAS; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trilipix (fenofibric acid) [prescribing information]. North Chicago, IL: Abbvie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: A practical approach for clinicians. <i>Obstet Med</i>. 2015;8(4):158-167. doi: 10.1177/1753495X15594082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/27512474/pubmed\" target=\"_blank\" id=\"27512474\">27512474</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91482 Version 186.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F49638570\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22370290\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22370293\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F22370331\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F22370332\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370333\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370334\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22549100\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F49638571\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F49638569\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22370348\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50134064\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F22625620\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22370337\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22370297\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F22370285\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22370307\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22370304\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22370305\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F22370312\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F22370313\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F22549098\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F22370300\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F22370301\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F22370303\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F22370336\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22370339\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22370318\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F22370320\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F22370351\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49626998\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91482|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fenofibrate-patient-drug-information\" class=\"drug drug_patient\">Fenofibrate: Patient drug information</a></li></ul></div></div>","javascript":null}